| 09.07 14:33 | dpa-AFX: *MERCK ANIMAL HEALTH CLOSES ACQUISITION OF ELANCO'S AQUA BUSINESS |
| 09.07 14:29 | dpa-AFX: *ELANCO COMPLETES SALE OF AQUA BUSINESS TO MERCK ANIMAL HEALTH |
| 09.07 13:40 | dpa-AFX: *PRELUDE ANNOUNCES CLINICAL COLLABORATION WITH MERCK TO EVALUATE PRT3789 WITH KEYTRUDA IN SMARCA4-MUTATED CANCERS |
| 09.07 13:40 | dpa-AFX: *PRELUDE, MERCK COLLABORATE TO EVALUATE PRT3789 - KEYTRUDA COMBINATION IN SMARCA4-MUTATED CANCERS |
| 02.07 22:08 | MÄRKTE USA/Freundlich - Kräftige Gewinne bei Autoaktien |
| 02.07 18:14 | MÄRKTE USA/Seitwärts in ruhigem Handel - Tesla auf Sechsmonatshoch |
| 01.07 22:10 | MÄRKTE USA/Freundlich - Technologieaktien favorisiert |
| 01.07 18:23 | MÄRKTE USA/Etwas fester - Marktzinsen steigen weiter |
| 01.07 15:22 | dpa-AFX: Orion Stock Up On FY24 Outlook Upgrade After Opevesostat Deal With Merck |
| 01.07 14:22 | dpa-AFX: *MERCK AND ORION GRANT GLOBAL RIGHTS FOR OPEVESOSTAT IN PROSTATE CANCER TREATMENT; ORION TO GET $975 MLN PAYMENTS |
| 01.07 14:20 | dpa-AFX: *MERCK AND ORION GRANT GLOBAL RIGHTS FOR OPEVESOSTAT IN PROSTATE CANCER TREATMENT |
| 28.06 14:43 | dpa-AFX: Merck: CHMP Recommends Approval Of WINREVAIR In Pulmonary Arterial Hypertension |
| 28.06 14:23 | dpa-AFX: *MERCK GETS POSITIVE EU CHMP OPINION FOR WINREVAIR IN PULMONARY ARTERIAL HYPERTENSION |
| 27.06 02:36 | dpa-AFX: Merck : FDA Issues Complete Response Letter For Patritumab Deruxtecan In EGFR-Mutated NSCLC |
| 26.06 08:00 | dpa-AFX: Merck : USDA Approves NOBIVAC NXT, First RNA-Particle Vaccine For Canine Flu H3N2 |
| 18.06 14:19 | dpa-AFX: Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults |
| 18.06 14:05 | dpa-AFX: *LIGAND SAYS MERCK RECEIVES FDA APPROVAL FOR PNEUMOCOCCAL 21-VALENT CONJUGATE VACCINE FOR ADULTS |
| 03.06 17:10 | dpa-AFX: Merck Says MRNA-4157-Keytruda Combination Data Shows Improvement In High-Risk Melanoma Patients |
| 03.06 16:05 | dpa-AFX: *MERCK : MRNA-4157-KEYTRUDA COMBINATION DATA SHOWS SUSTAINED BENEFITS IN HIGH-RISK MELANOMA PATIENTS |
| 03.06 04:32 | dpa-AFX: Immutep Collaborates With Merck To Evaluate Efti In Combination Therapy For Metastatic NSCLC |
|
|
